SlideShare una empresa de Scribd logo
1 de 40
Descargar para leer sin conexión
3rd$Annual$Execu.ve$Global$
Clinical$Trials$
Mitchell(Katz,(Ph.D.(
Execu3ve(Director,(Medical(Research(Opera3ons(
Purdue(Pharma(L.P.(
September(2012(
2(
Pharma’s$Largest$Layoffs$in$2012$
3(
CRO$Consolida.on$
!  INC(
"  Kendle(
!  Theorem(
"  Omnicare(
"  IBAH(
!  Pharmanet/i3(
"  Inven3ve(Health(
!  Private(Equity(
"  PPD(
"  RPS(
"  PRA(
4(
Outsourcing$Buzz$Words$
!  Partnerships(
!  Alliances(
!  Preferred(Models(
!  Hybrid(Models(
!  Func3onal(Models(
!  Transac3onal(Models(
!  Offshoring(
!  “Strategic(Rela3onships”(
5(
Johnson$&$Johnson$and$ICON$
#1(–(Failure(to(ensure(proper(monitoring(of(the(clinical(
inves3ga3ons([21(CFR(312.50(and(312.56(a)(
#2(–(Failure(to(ensure(that(an(inves3ga3on(was(conducted(in(
accordance(with(the(general(inves.ga.onal$plan$and(
protocols(as(specified(in(the(IND([21(CFR(312.50](
#3(–(Failure(to(secure(inves.gator$compliance$with(the(
inves3ga3onal(plan(and(applicable(FDA(regula3ons([21(CFR(
312.56(b)](
#4(–(Failure(to(ensure(that(only(inves3gators(who(were(
qualified(by(training(and(experience(were(selected(as(
appropriate(experts(to(inves3gate(a(drug([21(CFR(212.53(a)](
6(
7(
It’s$All$About$.$.$.$
(
(
QUALITY$
8(
Avoca$Quality$Consor.um$
(
Pharma(and(Biotech(members((to(date):(
!  Alexion(Pharmaceu3cals,(Amgen,(Astellas(Pharma,(AstraZeneca,(Biogen(
Idec,(BristoldMyers(Squibb,(Cerexa,(Cubist(Pharmaceu3cals,(Daiichi(
Sankyo,(Eli(Lilly(and(Company,(GlaxoSmithKline,(Grünenthal,(ImClone(
Systems,(Janssen(Research(&(Development,(Otsuka,(Pfizer,(Purdue,(and(
Roche(
CRO(members((to(date):(
!  Chiltern(Interna3onal,(Covance,(INC(Research,(ICON,(Harrison(Clinical(
Research,(PAREXEL(Interna3onal,(PharmaNet/i3,(PRA(Interna3onal,(
Quin3les,(Theorem(Clinical(Research,(and(RPS(
(
Corporate(Sponsors:(
Quality$Management$and$CRO$
Oversight$
10(
Agenda$
!  Overview:(Background(and(context(
!  Part$1:(Overall(percep3ons(and(the(
“disconnects”(between(sponsors(and(CROs(
around(issues(of(quality(
!  Part$2:(Root(causes(of(quality(issues(and(the(
issue(of(“micromanagement”(
!  Part$3:(Best(prac3ce(approaches(associated(
with(sa3sfac3on(
!  Open(discussion(
11(
Context$for$Research$on$Quality$and$
CRO$Oversight$
!  Increase(in(clinical(outsourcing(
!  Consolida3on(of(spend(with(few(clinical(service(providers(
!  Globaliza3on(of(clinical(trials:(increase(in(number(of(studies(in(lessdexperienced(developing(
regions(
!  Focus(on(efficiencies(and(cost(savings(
!  Increase(in(the(number(of(highdprofile(FDA(warning(lemers(
Focus(on(Avoca’s(2011(Industry(Survey:(percep3ons(from(sponsors(and(CROs(on(the(quality(of(
outsourced(trials(
Focus(of(Avoca’s(Quality(Consor3um:(proac3ve(quality(management(
The$focus$and$vision$of$the$Quality$Consor5um$are$to$accelerate$the$development$of$an$industry$
standard$and$best9prac5ce$approach$to$the$quality$management$of$outsourced$trials$through$the$
sharing$of$best$prac5ces$
12(
Methods$
!  Surveys(explored(respondents’(views(and(experiences(regarding:(
"  Sa3sfac3on(with(quality(of(work(delivered(by(clinical(service(providers(
"  Approaches(to(managing(quality(in(outsourced(clinical(trials,(including(
quality(metrics,(repor3ng(tools,(and(desktop(analy3cs(
"  Scope(and(u3lity(of(Quality(Agreements(
"  Other(tools(used(to(set(expecta3ons(for(quality(in(outsourced(clinical(
trials(
"  Quality(concerns(and(management(when(outsourcing(in(Emerging(
Markets(
"  Quality(considera3ons(in(selec3ng(CROs(
13(
2011$Industry$Survey$
!  104(sponsor(surveys(from(66(
companies(
"  73%(pharma,(
17%(biotech(
"  52%(“Top(20”(
"  44%(Opera3ons,(
40%(Outsourcing(
"  17%(execu3ves,(
58%(middle(management((
!  143(provider(surveys(from(88(
companies(
"  78%(CROs(
"  64%(“Top(20”(
"  38%(Opera3ons,(
31%(BD,(
22%(Management(
"  48%(execu3ves,(
39%(middle(management((
247(Surveys(
14(
Quality$Consor.um$Assessment$
!  428(sponsor(surveys(were(deployed(resul3ng(in(feedback(from(334(
individuals(
"  Overall(response(rate:(78%(
"  Completed(surveys/company:(10d46((note(that(there(was(no(associa3on(
between(company(size(and(number(of(respondents)(
"  Range(of(response(rates/company:(50%d100%(
!  298(CRO(surveys(were(deployed(resul3ng(in(feedback(from(207(individuals(
"  Overall(response(rate:(69%(
"  Completed(surveys/company:(4d59((note(that(there(was(no(associa3on(
between(company(size(and(number(of(respondents)(
"  Range(of(response(rates/company:(27%d100%(
Part$1:$$Framing$the$Quality$Issue$
Overall(percep3ons(and(the(
“disconnects”(between(sponsors(and(
CROs(around(issues(of(quality(
16(
Methods$
!  “Quality”(was(defined(as(“The$ability$to$effec.vely$and$efficiently$answer$
the$intended$ques.on$about$the$benefits$and$risks$of$a$medical$product$
or$procedure$while$assuring$pa.ent$safety$and$protec.on$of$human$
subjects”$
!  As(examples,(elements(of(a(quality(clinical(study(were(said(to(include,(but(
not(limited(to:(
"  Scien3fically(valid(and(ethically(sound(experimental(design(
"  Adequate(protec3on(of(subjects’(rights,(safety(and(welfare(
"  Qualified(personnel(
"  Adequate(monitoring(
"  Current,(complete,(and(accurate(data(
"  Accurate(presenta3on(and(interpreta3on(of(data(
17(
Industry$Survey$Sponsors:$Overall$
Sa.sfac.on$
18(
Consor.um$Sponsors:$Sa.sfac.on$
with$Quality$
19(
Consor.um$Sponsors:$Comparison$of$
CRO$Quality$to$Sponsor$Internal$
Teams$
20(
Sa.sfac.on$with$Quality$
21(
Industry$Survey:$Provider$Sa.sfac.on$
22(
Sponsors:$Sa.sfac.on$with$Quality$
Areas(with(rela3vely(high(sa3sfac3on(included:(
!  Compliance(with(SOPs(and(other(wrimen(procedures(
!  Data$quality$and$integrity$
!  Audit(plans(and(execu3on(
Areas(with(rela3vely(high(dissa3sfac3on(included:(
!  Oversight(of(third(party(vendors(
!  Governance(of(quality(
!  Communica3ons(surrounding(quality(
!  Availability(of(quality(personnel(for(projects(
!  Efficiency/.meliness$in$achieving$clean$data$
!  Adherence(to(monitoring(plan(
Part$2:$$Causes$of$Quality$Issues$
24(
Causes$of$Issues$with$Quality$
“CROs,$as$service$providers,$are$heavily$incented$to$
deliver$and$measure$quality$–$and$are$prepared$to$do$
so.$$Too$many$sponsors$are$not$prepared$to$do$their$
part$in$assuring$a$rela5onship$focused$on$quality.$$So$
CROs$are$forced$to$implement$one$model$for$sponsors$
ready$to$focus$on$quality,$and$another$for$the$many$
focused$on$ac5vi5es$and$unit9level$cost.”$
( ( (d(Quota3on(from(an(Industry(Survey(Provider(Respondent(
(
(
25(
Causes$of$Issues$with$Quality:$Sponsor$
Consor.um$Data$
26(
Industry$Survey:$Causes$of$Issues$with$
Quality$
27(
Quality$vs.$Costs$
28(
Causes$of$Issues$with$Quality$
#1:$Cost$Pressures$
“The$focus$on$price$has$driven$out$the$reality$of$adequate$
monitoring$and$proper$Quality$Control$processes$to$ensure$quality$
at$the$site$level…$Too$many$procurement$officers$are$making$
decisions$purely$on$cost$without$regards$to$quality$product.”$
“Price$pressures,$especially$discounts…have$caused$some$CROs$to$
cut$corners$and$send$work$to$low$cost$regions$without$adequately$
trained$staff.”$
“Price$reduc5ons$required$to$‘play$the$game’$in$the$preferred$
provider$selec5on$process$make$it$very$difficult$to$con5nue$to$
resource$adequately.$$Sponsors$say$they$will$streamline$processes$
going$forward$to$reduce$workload$but$hardly$ever$do.”$
29(
Causes$of$Issues$with$Quality$
#2:(Sponsors(DecisiondMaking(with(
Impacts(on(Quality((without(provider(
input)(
!  Oversight((level(of(monitoring)(
!  Protocol(design(
!  Inves3gators(&(regions(
!  Timelines(
!  Processes(
!  Thirddparty(vendors(
“It$is$difficult$to$ensure$quality$for$a$func5onal$provider$for$monitoring,$when$
the$protocol$design/site$selec5on$are$done$by$another$CRO/sponsor.”$
“There$is$a$percentage$of$work$that$we$perform$that$is$working$with$the$
sponsor$processes,$etc…in$these$circumstances,$quality,$5meliness,$training,$
governance$and$oversight$are$dictated$by$sponsor$requirements.”$
30(
Causes$of$Issues$with$Quality$
#3:$Sponsor$Failure$to$Proac.vely$Make$Decisions$or$
Communicate$with$Providers$about$Quality$Expecta.ons$
Industry(survey(data:(
!  Only(55%(of(sponsors(are(sa3sfied(with(their(companies’(iden3fica3on(of(process/
deliverables(for(which(quality(expecta3ons(of(CROs(need(to(be(set.(
!  Only(58%(feel(that(their(companies(effec3vely(communicate(quality(expecta3ons(
to(CROs(
!  Strong(associa3on(between(“proac3ve”(management(of(quality(and(ability(to(
forego(micromanagement.(
Part$3:$$Results$
What(can(be(done(to(enhance(quality(while(
reducing(micromanagement?(
What$quality$prac.ces$are$associated$with$
enhanced$sa.sfac.on?$
32(
Industry$Survey$Sponsors:$Quality$
Metrics$
33(
Consor.um$Survey:$Quality$Metrics$
34(
Quality$Agreements$
35(
Industry$Survey$Sponsors:$Quality$
Agreements$
36(
Industry$Survey$Sponsors:$Quality$
Agreements$
37(
Other$Prac.ces$Impac.ng$Quality$
Risk$Based$Approaches$
!  57%(of(sponsors(and(58%(of(CROs(use(a(formal,(riskdbased(
approach(to(levels(of(site(monitoring((industry(survey(data)(
"  About(2/3(have(had(primarily(posi3ve(experiences(–(1/3(mixed(
!  Most(sponsors((67%)(and(CROs((79%)(do(maintain(
documenta3on(of(site(performance(on(previous(trials(to(
factors(into(such(models.(
"  Performance(data(most(commonly(includes(number(of(protocol(
viola3ons,(number(of(queries,(type(and(severity(of(protocol(
viola3ons,(promptness(of(data(entry,(types(of(queries,(and(3me(
to(resolu3on(of(queries.(
38(
Quality$by$Region$
39(
Summary$
!  While(developing(standards(and(more(
efficient(ways(for(sponsors(and(CROs(to(work(
together(is(necessary,(it(has(been(
challenging.(
!  There(is(greater(poten3al(for(success(in(
terms(of(the(ability(to(quickly(move(towards(
standards:(
( ( (Quality(Agreements(
( ( (Quality(Metrics(
!  There(is(no(onedsize(fits(all(CRO(model(
Open$Discussion$
(
Thank(You(

Más contenido relacionado

Similar a A Peek at GCT 2012

2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docxeugeniadean34240
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Ankur Khanna
 
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignA Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignRichard Hogue
 
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Chirag Patel
 
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Sean Ekins
 
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoveryTranslational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoverypharmaindexing
 
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...Stockholm Institute of Transition Economics
 
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolKnowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolChristine Wekerle
 
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docxRunning head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docxhealdkathaleen
 
New Product Planning and Medical Affairs
New Product Planning and Medical AffairsNew Product Planning and Medical Affairs
New Product Planning and Medical AffairsAnthony Russell
 
Implicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsImplicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsSrinidhi Boray
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process KerentechEstherMM
 
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...Joanne Sienko Ott, CFA, MA
 
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxRoddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxSUBHI7
 
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text FinalKnowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Finalkdjamies
 
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryMel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryJean-Claude Bradley
 

Similar a A Peek at GCT 2012 (20)

2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
 
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
 
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare DesignA Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare Design
 
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416
 
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
 
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discoveryTranslational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discovery
 
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
 
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call toolKnowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call tool
 
Searching for Relevant Studies
Searching for Relevant StudiesSearching for Relevant Studies
Searching for Relevant Studies
 
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docxRunning head  HEALTH PROMOTION IN MINORITY POPULATIONS           .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
 
New Product Planning and Medical Affairs
New Product Planning and Medical AffairsNew Product Planning and Medical Affairs
New Product Planning and Medical Affairs
 
Implicate order Probabilistic Semantics
Implicate order Probabilistic SemanticsImplicate order Probabilistic Semantics
Implicate order Probabilistic Semantics
 
The Drug Development Process Kerentech
The Drug Development Process KerentechThe Drug Development Process Kerentech
The Drug Development Process Kerentech
 
When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...
 
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
 
apcp Deeksha Bhartiya
apcp Deeksha  Bhartiyaapcp Deeksha  Bhartiya
apcp Deeksha Bhartiya
 
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docxRoddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
 
Literature Review on Health & Safety
Literature Review on Health & SafetyLiterature Review on Health & Safety
Literature Review on Health & Safety
 
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text FinalKnowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Final
 
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug DiscoveryMel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
 

Más de ConferenceForum

Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsConferenceForum
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkConferenceForum
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsConferenceForum
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...ConferenceForum
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerConferenceForum
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012ConferenceForum
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontnyConferenceForum
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1ConferenceForum
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012ConferenceForum
 

Más de ConferenceForum (17)

A Peek at Dpharm 2012
A Peek at Dpharm 2012A Peek at Dpharm 2012
A Peek at Dpharm 2012
 
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & BiosimilarsStrategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
 
Scott Harris
Scott HarrisScott Harris
Scott Harris
 
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the TalkThomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
 
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging MarketsGCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging Markets
 
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
 
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz StonerChanging Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz Stoner
 
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Ian sanderson
Ian sandersonIan sanderson
Ian sanderson
 
Podd slides 1
Podd slides 1Podd slides 1
Podd slides 1
 
Podd slides
Podd slidesPodd slides
Podd slides
 
Podd slide deck mark kontny
Podd slide deck   mark kontnyPodd slide deck   mark kontny
Podd slide deck mark kontny
 
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1
 
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012
 
Sohini Chowdhury, 2011
Sohini Chowdhury, 2011Sohini Chowdhury, 2011
Sohini Chowdhury, 2011
 

Último

Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateStrategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateAdnet Communications
 
PHX Corporate Presentation March 2024 Final
PHX Corporate Presentation March 2024 FinalPHX Corporate Presentation March 2024 Final
PHX Corporate Presentation March 2024 FinalPanhandleOilandGas
 
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptBus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptendeworku
 
NewBase 14 March 2024 Energy News issue - 1707 by Khaled Al Awadi_compress...
NewBase  14 March  2024  Energy News issue - 1707 by Khaled Al Awadi_compress...NewBase  14 March  2024  Energy News issue - 1707 by Khaled Al Awadi_compress...
NewBase 14 March 2024 Energy News issue - 1707 by Khaled Al Awadi_compress...Khaled Al Awadi
 
Shopclues: Failure & Solutions in Business Model
Shopclues: Failure & Solutions in Business ModelShopclues: Failure & Solutions in Business Model
Shopclues: Failure & Solutions in Business ModelBhaviniSharma12
 
Business Models and Business Model Innovation
Business Models and Business Model InnovationBusiness Models and Business Model Innovation
Business Models and Business Model InnovationMichal Hron
 
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfA Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfmeftaul987
 
L-1 VISA Business (Plan Sample) - Plan Writers
L-1 VISA Business (Plan Sample) - Plan WritersL-1 VISA Business (Plan Sample) - Plan Writers
L-1 VISA Business (Plan Sample) - Plan WritersPlan Writers
 
AirOxi - Pioneering Aquaculture Advancements Through NFDB Empanelment.pptx
AirOxi -  Pioneering Aquaculture Advancements Through NFDB Empanelment.pptxAirOxi -  Pioneering Aquaculture Advancements Through NFDB Empanelment.pptx
AirOxi - Pioneering Aquaculture Advancements Through NFDB Empanelment.pptxAirOxi Tube
 
Green Innovations: Wristbands Ireland's Eco-Friendly Products
Green Innovations: Wristbands Ireland's Eco-Friendly ProductsGreen Innovations: Wristbands Ireland's Eco-Friendly Products
Green Innovations: Wristbands Ireland's Eco-Friendly ProductsWristbands Ireland
 
NVIDIA's overall business overview Presentation.pptx
NVIDIA's overall business overview Presentation.pptxNVIDIA's overall business overview Presentation.pptx
NVIDIA's overall business overview Presentation.pptxKrutik Rakade
 
Presented by Sabri international .......
Presented by Sabri international .......Presented by Sabri international .......
Presented by Sabri international .......SABRI INTERNATIONAL
 
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in EgyptMist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egyptopstechsanjanasingh
 
EPC Contractors aspects Presentation.pdf
EPC Contractors  aspects Presentation.pdfEPC Contractors  aspects Presentation.pdf
EPC Contractors aspects Presentation.pdfGiuseppe Tommasone
 
Optimize Your CRM Customization and Beyond
Optimize Your CRM Customization and BeyondOptimize Your CRM Customization and Beyond
Optimize Your CRM Customization and BeyondBoundify
 
How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersHow The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersFlyyx Tech
 
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxA Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxShainaMaheshwari1
 
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan BusinessUnleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Businesstompeter3736
 
"InShorts: A Game-Changer in the Digital News Age"
"InShorts: A Game-Changer in the Digital News Age""InShorts: A Game-Changer in the Digital News Age"
"InShorts: A Game-Changer in the Digital News Age"Adharsh45
 

Último (20)

Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 UpdateStrategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 Update
 
PHX Corporate Presentation March 2024 Final
PHX Corporate Presentation March 2024 FinalPHX Corporate Presentation March 2024 Final
PHX Corporate Presentation March 2024 Final
 
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities pptBus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
 
WAM Corporate Presentation Mar 12 2024.pdf
WAM Corporate Presentation Mar 12 2024.pdfWAM Corporate Presentation Mar 12 2024.pdf
WAM Corporate Presentation Mar 12 2024.pdf
 
NewBase 14 March 2024 Energy News issue - 1707 by Khaled Al Awadi_compress...
NewBase  14 March  2024  Energy News issue - 1707 by Khaled Al Awadi_compress...NewBase  14 March  2024  Energy News issue - 1707 by Khaled Al Awadi_compress...
NewBase 14 March 2024 Energy News issue - 1707 by Khaled Al Awadi_compress...
 
Shopclues: Failure & Solutions in Business Model
Shopclues: Failure & Solutions in Business ModelShopclues: Failure & Solutions in Business Model
Shopclues: Failure & Solutions in Business Model
 
Business Models and Business Model Innovation
Business Models and Business Model InnovationBusiness Models and Business Model Innovation
Business Models and Business Model Innovation
 
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdfA Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdf
 
L-1 VISA Business (Plan Sample) - Plan Writers
L-1 VISA Business (Plan Sample) - Plan WritersL-1 VISA Business (Plan Sample) - Plan Writers
L-1 VISA Business (Plan Sample) - Plan Writers
 
AirOxi - Pioneering Aquaculture Advancements Through NFDB Empanelment.pptx
AirOxi -  Pioneering Aquaculture Advancements Through NFDB Empanelment.pptxAirOxi -  Pioneering Aquaculture Advancements Through NFDB Empanelment.pptx
AirOxi - Pioneering Aquaculture Advancements Through NFDB Empanelment.pptx
 
Green Innovations: Wristbands Ireland's Eco-Friendly Products
Green Innovations: Wristbands Ireland's Eco-Friendly ProductsGreen Innovations: Wristbands Ireland's Eco-Friendly Products
Green Innovations: Wristbands Ireland's Eco-Friendly Products
 
NVIDIA's overall business overview Presentation.pptx
NVIDIA's overall business overview Presentation.pptxNVIDIA's overall business overview Presentation.pptx
NVIDIA's overall business overview Presentation.pptx
 
Presented by Sabri international .......
Presented by Sabri international .......Presented by Sabri international .......
Presented by Sabri international .......
 
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in EgyptMist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egypt
 
EPC Contractors aspects Presentation.pdf
EPC Contractors  aspects Presentation.pdfEPC Contractors  aspects Presentation.pdf
EPC Contractors aspects Presentation.pdf
 
Optimize Your CRM Customization and Beyond
Optimize Your CRM Customization and BeyondOptimize Your CRM Customization and Beyond
Optimize Your CRM Customization and Beyond
 
How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K SubscribersHow The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K Subscribers
 
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptxA Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
 
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan BusinessUnleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Business
 
"InShorts: A Game-Changer in the Digital News Age"
"InShorts: A Game-Changer in the Digital News Age""InShorts: A Game-Changer in the Digital News Age"
"InShorts: A Game-Changer in the Digital News Age"
 

A Peek at GCT 2012